2025 Annual A-Share Issuance Prospectus for Specific Objects (Revised Draft)

1-1-1 Securities Code: 002940
Securities Abbreviation: AngLiKang
Zhejiang AngLiKang Pharmaceutical Co., Ltd. (1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province)
2025 Annual A-Share Issuance Prospectus for Specific Objects (Revised Draft)
Sponsor (Lead Underwriter): Orient Securities Building, 119 South Zhongshan Road, Huangpu District, Shanghai
May 2026

Zhejiang AngLiKang Pharmaceutical Co., Ltd.
Prospectus (Revised Draft)

1-1-1 Statement
The company and all directors, members of the audit committee, and senior management commit that the content of this prospectus and other information disclosure materials do not contain false records, misleading statements, or major omissions, and bear corresponding legal responsibilities for the authenticity, accuracy, and completeness. The person in charge of the company, the person responsible for accounting work, and the head of the accounting institution guarantee that the financial accounting data in the prospectus is true and complete. The China Securities Regulatory Commission and the Shenzhen Stock Exchange do not guarantee the authenticity, accuracy, or completeness of the application documents and disclosed information regarding this issuance, nor do they make substantive judgments or guarantees regarding the issuer's profitability, investment value, or investor returns. Any contrary statements are false and misleading. According to the Securities Law, after the securities are legally issued, the issuer is responsible for changes in operations and earnings, investors independently assess the issuer's investment value, make their own investment decisions, and bear the investment risks arising from changes in the issuer's operations and earnings or fluctuations in securities prices after the legal issuance of securities.

1-1-2 Major Matters Reminder
The company particularly reminds investors to carefully read the main content of this prospectus before making investment decisions and pay special attention to the following important matters and company risks.